Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy

Bina Shah, Emily Breidbart, Melissa Pawelczak, Leslie S. Lam, Marion Kessler, Bonita Franklin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Activating mutations of the ABCC8 gene can lead to permanent neonatal diabetes mellitus (PNDM). Glucose variability in infants with NDM treated with insulin can be extreme. We report long-term glycemic control in a patient with PNDM on sulfonylurea therapy, despite initial allergic reaction. Methods: A Chinese girl presented on the first day of life with persistent hyperglycemia. Despite treatment with various insulin regimens, hemoglobin (Hb) A1c (normal 4.8%-6.3%) increased from 5.0% at 14 days of age to a peak of 9.7% at 15 months of age. Her average insulin dose was 0.5 units/kg/day. Genetic analysis revealed two novel ABCC8 gene activating mutations encoding the β-cell sulfonylurea-1 receptor of the ATP-sensitive potassium channel. At age 3 years 2 months, transition from insulin to the oral sulfonylurea glyburide was initiated. After 8 days, she developed urticaria, palmar erythema, and a diffuse maculopapular rash, which resolved when medication was discontinued. At age 3 years 11 months, glyburide was reintroduced at a very low dose and was increased with concomitant weaning of insulin over the following 6 months. Results: Normoglycemia (HbA 1c 5.6%) was achieved on glyburide without any further allergic reaction at the age of 4 years 5 months with improved metabolic control. For the next 3 years, HbA 1c measurements, and glucose means and variability were significantly lower compared with values during insulin therapy. Conclusions: As compared with subcutaneous insulin, oral sulfonylureas improved long-term metabolic control in a patient with NDM caused by novel activating mutations in the ABCC8 gene. Desensitization permitted safe oral sulfonylurea therapy in our patient with NDM despite initial allergic reaction. Fewer episodes of hypoglycemia occurred on sulfonylurea than on insulin therapy, which is an advantage in a very young child.

Original languageEnglish (US)
Pages (from-to)353-356
Number of pages4
JournalJournal of Pediatric Endocrinology and Metabolism
Volume25
Issue number3-4
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Diabetes Mellitus
Hypersensitivity
Insulin
Glucose
Glyburide
Mutation
Sulfonylurea Receptors
Genes
Therapeutics
KATP Channels
Urticaria
Erythema
Exanthema
Weaning
Hypoglycemia
Hyperglycemia
Hemoglobins

Keywords

  • neonatal diabetes
  • sulfonylurea

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy. / Shah, Bina; Breidbart, Emily; Pawelczak, Melissa; Lam, Leslie S.; Kessler, Marion; Franklin, Bonita.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 25, No. 3-4, 01.04.2012, p. 353-356.

Research output: Contribution to journalArticle

Shah, Bina ; Breidbart, Emily ; Pawelczak, Melissa ; Lam, Leslie S. ; Kessler, Marion ; Franklin, Bonita. / Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy. In: Journal of Pediatric Endocrinology and Metabolism. 2012 ; Vol. 25, No. 3-4. pp. 353-356.
@article{78b1b2ad2f634c50b3c34e2d22d9d9b3,
title = "Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy",
abstract = "Background: Activating mutations of the ABCC8 gene can lead to permanent neonatal diabetes mellitus (PNDM). Glucose variability in infants with NDM treated with insulin can be extreme. We report long-term glycemic control in a patient with PNDM on sulfonylurea therapy, despite initial allergic reaction. Methods: A Chinese girl presented on the first day of life with persistent hyperglycemia. Despite treatment with various insulin regimens, hemoglobin (Hb) A1c (normal 4.8{\%}-6.3{\%}) increased from 5.0{\%} at 14 days of age to a peak of 9.7{\%} at 15 months of age. Her average insulin dose was 0.5 units/kg/day. Genetic analysis revealed two novel ABCC8 gene activating mutations encoding the β-cell sulfonylurea-1 receptor of the ATP-sensitive potassium channel. At age 3 years 2 months, transition from insulin to the oral sulfonylurea glyburide was initiated. After 8 days, she developed urticaria, palmar erythema, and a diffuse maculopapular rash, which resolved when medication was discontinued. At age 3 years 11 months, glyburide was reintroduced at a very low dose and was increased with concomitant weaning of insulin over the following 6 months. Results: Normoglycemia (HbA 1c 5.6{\%}) was achieved on glyburide without any further allergic reaction at the age of 4 years 5 months with improved metabolic control. For the next 3 years, HbA 1c measurements, and glucose means and variability were significantly lower compared with values during insulin therapy. Conclusions: As compared with subcutaneous insulin, oral sulfonylureas improved long-term metabolic control in a patient with NDM caused by novel activating mutations in the ABCC8 gene. Desensitization permitted safe oral sulfonylurea therapy in our patient with NDM despite initial allergic reaction. Fewer episodes of hypoglycemia occurred on sulfonylurea than on insulin therapy, which is an advantage in a very young child.",
keywords = "neonatal diabetes, sulfonylurea",
author = "Bina Shah and Emily Breidbart and Melissa Pawelczak and Lam, {Leslie S.} and Marion Kessler and Bonita Franklin",
year = "2012",
month = "4",
day = "1",
doi = "10.1515/jpem-2011-0449",
language = "English (US)",
volume = "25",
pages = "353--356",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "3-4",

}

TY - JOUR

T1 - Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy

AU - Shah, Bina

AU - Breidbart, Emily

AU - Pawelczak, Melissa

AU - Lam, Leslie S.

AU - Kessler, Marion

AU - Franklin, Bonita

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background: Activating mutations of the ABCC8 gene can lead to permanent neonatal diabetes mellitus (PNDM). Glucose variability in infants with NDM treated with insulin can be extreme. We report long-term glycemic control in a patient with PNDM on sulfonylurea therapy, despite initial allergic reaction. Methods: A Chinese girl presented on the first day of life with persistent hyperglycemia. Despite treatment with various insulin regimens, hemoglobin (Hb) A1c (normal 4.8%-6.3%) increased from 5.0% at 14 days of age to a peak of 9.7% at 15 months of age. Her average insulin dose was 0.5 units/kg/day. Genetic analysis revealed two novel ABCC8 gene activating mutations encoding the β-cell sulfonylurea-1 receptor of the ATP-sensitive potassium channel. At age 3 years 2 months, transition from insulin to the oral sulfonylurea glyburide was initiated. After 8 days, she developed urticaria, palmar erythema, and a diffuse maculopapular rash, which resolved when medication was discontinued. At age 3 years 11 months, glyburide was reintroduced at a very low dose and was increased with concomitant weaning of insulin over the following 6 months. Results: Normoglycemia (HbA 1c 5.6%) was achieved on glyburide without any further allergic reaction at the age of 4 years 5 months with improved metabolic control. For the next 3 years, HbA 1c measurements, and glucose means and variability were significantly lower compared with values during insulin therapy. Conclusions: As compared with subcutaneous insulin, oral sulfonylureas improved long-term metabolic control in a patient with NDM caused by novel activating mutations in the ABCC8 gene. Desensitization permitted safe oral sulfonylurea therapy in our patient with NDM despite initial allergic reaction. Fewer episodes of hypoglycemia occurred on sulfonylurea than on insulin therapy, which is an advantage in a very young child.

AB - Background: Activating mutations of the ABCC8 gene can lead to permanent neonatal diabetes mellitus (PNDM). Glucose variability in infants with NDM treated with insulin can be extreme. We report long-term glycemic control in a patient with PNDM on sulfonylurea therapy, despite initial allergic reaction. Methods: A Chinese girl presented on the first day of life with persistent hyperglycemia. Despite treatment with various insulin regimens, hemoglobin (Hb) A1c (normal 4.8%-6.3%) increased from 5.0% at 14 days of age to a peak of 9.7% at 15 months of age. Her average insulin dose was 0.5 units/kg/day. Genetic analysis revealed two novel ABCC8 gene activating mutations encoding the β-cell sulfonylurea-1 receptor of the ATP-sensitive potassium channel. At age 3 years 2 months, transition from insulin to the oral sulfonylurea glyburide was initiated. After 8 days, she developed urticaria, palmar erythema, and a diffuse maculopapular rash, which resolved when medication was discontinued. At age 3 years 11 months, glyburide was reintroduced at a very low dose and was increased with concomitant weaning of insulin over the following 6 months. Results: Normoglycemia (HbA 1c 5.6%) was achieved on glyburide without any further allergic reaction at the age of 4 years 5 months with improved metabolic control. For the next 3 years, HbA 1c measurements, and glucose means and variability were significantly lower compared with values during insulin therapy. Conclusions: As compared with subcutaneous insulin, oral sulfonylureas improved long-term metabolic control in a patient with NDM caused by novel activating mutations in the ABCC8 gene. Desensitization permitted safe oral sulfonylurea therapy in our patient with NDM despite initial allergic reaction. Fewer episodes of hypoglycemia occurred on sulfonylurea than on insulin therapy, which is an advantage in a very young child.

KW - neonatal diabetes

KW - sulfonylurea

UR - http://www.scopus.com/inward/record.url?scp=84861631760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861631760&partnerID=8YFLogxK

U2 - 10.1515/jpem-2011-0449

DO - 10.1515/jpem-2011-0449

M3 - Article

VL - 25

SP - 353

EP - 356

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 3-4

ER -